|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Net product revenue | |||||
| Collaboration revenue | |||||
| Collaboration and license revenue | |||||
| Royalty revenue | |||||
| Translarna | |||||
| Manufacturing revenue | |||||
| Total revenues | |||||
| Operating expenses: | |||||
| Cost of product, collaboration and license sales, excluding amortization of acquired intangible assets | |||||
| Amortization of acquired intangible assets | |||||
| Research and development | |||||
| Selling, general and administrative | |||||
| Change in the fair value of contingent consideration | |||||
| Intangible asset impairment | |||||
| Tangible asset impairment and (gains) losses on transactions, net | |||||
| Total operating expenses | |||||
| Income (loss) from operations | |||||
| Interest expense, net | |||||
| Other (expense) income, net | |||||
| Gain on sale of priority review voucher | |||||
| Loss on extinguishment of debt | |||||
| Income (loss) before income tax (expense) benefit | |||||
| Income tax (expense) benefit | |||||
| Net income (loss) attributable to common stockholders | |||||
| Weighted-average shares outstanding: | |||||
| Basic (in shares) | |||||
| Diluted (in shares) | |||||
| Net income (loss) per share-basic and diluted (in dollars per share) | |||||
| Basic | |||||
| Diluted |
Loading...
